Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12124653 | 0.75 | AR (0.50) | ARGRM5NPSR1VCPAGTR2 | |
| SCHEMBL19823672 | 0.70 | AR (0.61) | ARGRM5NPSR1NPC1 | |
| SCHEMBL1657048 | 0.69 | AR (0.50) | ARGRM5NPSR1AGTR2 | |
| SCHEMBL4118601 | 0.68 | AR (0.52) | ARGRM5NPSR1VCPMEN1 | |
| SCHEMBL2474223 | 0.68 | AR (0.64) | ARGRM5NPSR1VCPMEN1 | |
| SCHEMBL24416093 | 0.68 | AR (0.60) | ARGRM5NPSR1MEN1NPC1 | |
| SCHEMBL2342238 | 0.66 | AR (0.57) | ARGRM5NPSR1SIGMAR1POLB | |
| SCHEMBL17954204 | 0.65 | LMNA (0.62) | ARGRM5SIGMAR1RAB9A | |
| Hydrochloric Acid SCHEMBL22031493 | 0.65 | AR (0.56) | ARGRM5NPSR1SIGMAR1POLB | |
| SCHEMBL5940654 | 0.64 | AR (0.61) | ARGRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRNA10, ACHE, SNCA | AR 3030/4885GRM5 336/4885NPSR1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.